Browse Category

NASDAQ:RMD News 10 January 2026

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie shares fell 1.8% to $220.08 after the company cut its 2025 earnings forecast and denied takeover talks with Revolution Medicines. AbbVie now expects Q4 adjusted EPS of $2.61–$2.65, down from $3.32–$3.36, and full-year EPS of $9.90–$9.94. The company cited $1.265 billion in R&D and milestone charges. AbbVie said its fourth-quarter results are preliminary.

Stock Market Today

Verizon stock snaps seven-day winning streak — what to watch for VZ into the new week

Verizon stock snaps seven-day winning streak — what to watch for VZ into the new week

8 February 2026
Verizon shares fell 1.7% to $46.31 on Friday, ending a seven-day rally and lagging a broad market rebound. The drop follows a leadership shakeup in the consumer unit, with Sowmyanarayan Sampath stepping down and Alfonso Villanueva named interim chief. Investors await delayed U.S. jobs and inflation data next week, which could affect rate-sensitive stocks.
Go toTop